FitLife Brands (FTLF) Competitors

Relay Therapeutics (NASDAQ:RLAY) and FitLife Brands (NASDAQ:FTLF) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, media sentiment, community ranking, profitability, risk and earnings.

Which has stronger earnings & valuation, RLAY or FTLF?

FitLife Brands has higher revenue and earnings than Relay Therapeutics. Relay Therapeutics is trading at a lower price-to-earnings ratio than FitLife Brands, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relay Therapeutics	$10.01M	44.38	-$341.97M	-$2.39	-1.10
FitLife Brands	$62.76M	1.78	$5.30M	$0.84	14.40

Which has more risk & volatility, RLAY or FTLF?

Relay Therapeutics has a beta of 1.65, suggesting that its stock price is 65% more volatile than the S&P 500. Comparatively, FitLife Brands has a beta of 0.95, suggesting that its stock price is 5% less volatile than the S&P 500.

Does the media prefer RLAY or FTLF?

In the previous week, FitLife Brands had 5 more articles in the media than Relay Therapeutics. MarketBeat recorded 16 mentions for FitLife Brands and 11 mentions for Relay Therapeutics. Relay Therapeutics' average media sentiment score of 0.55 beat FitLife Brands' score of 0.28 indicating that Relay Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Relay Therapeutics	3 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
FitLife Brands	3 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do analysts recommend RLAY or FTLF?

Relay Therapeutics currently has a consensus price target of $19.80, suggesting a potential upside of 655.73%. FitLife Brands has a consensus price target of $20.50, suggesting a potential upside of 69.42%. Given Relay Therapeutics' higher probable upside, equities research analysts clearly believe Relay Therapeutics is more favorable than FitLife Brands.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relay Therapeutics	0 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.90
FitLife Brands	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.33

Is RLAY or FTLF more profitable?

FitLife Brands has a net margin of 13.38% compared to Relay Therapeutics' net margin of 0.00%. FitLife Brands' return on equity of 28.03% beat Relay Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relay Therapeutics	N/A	-45.75%	-40.75%
FitLife Brands	13.38%	28.03%	15.13%

Does the MarketBeat Community favor RLAY or FTLF?

Relay Therapeutics received 59 more outperform votes than FitLife Brands when rated by MarketBeat users. Likewise, 70.45% of users gave Relay Therapeutics an outperform vote while only 60.00% of users gave FitLife Brands an outperform vote.

Company	Underperform	Outperform
Relay Therapeutics	Outperform Votes 62 70.45%	Underperform Votes 26 29.55%
FitLife Brands	Outperform Votes 3 60.00%	Underperform Votes 2 40.00%

Do institutionals and insiders hold more shares of RLAY or FTLF?

97.0% of Relay Therapeutics shares are owned by institutional investors. Comparatively, 2.3% of FitLife Brands shares are owned by institutional investors. 4.3% of Relay Therapeutics shares are owned by insiders. Comparatively, 61.3% of FitLife Brands shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

FitLife Brands beats Relay Therapeutics on 11 of the 19 factors compared between the two stocks.